StocksMedium•9 November 2026•
1 min read
Viridian Therapeutics Announces Positive Phase 1 Results for VRDN-008
Key Facts
1Viridian Therapeutics announced positive Phase 1 results for VRDN-008, supporting a potential every-8-week subcutaneous dosing profile.
Viridian Therapeutics announced positive Phase 1 results for VRDN-008, supporting a potential every-8-week subcutaneous dosing profile. The company said in a statement via Business Wire that the data demonstrated a profile allowing for deep and sustained FcRn inhibition with infrequent dosing.
The findings support the development of a potential best-in-class medicine for autoimmune and rare diseases with a more convenient dosing schedule than current treatments. Shares of Viridian Therapeutics, trading under the ticker VRDN, closed at $28.49 on November 6, 2026.